title: Leukotriene receptor antagonists--an update.
abstract: Montelukast (Singulair-MSD) and zafirlukast (Accolate-AstraZeneca) are oral leukotriene receptor antagonists, licensed for the treatment of patients with asthma. In 1998, soon after their launch, we concluded that there was insufficient evidence to clearly define their place in treatment. Here, we reconsider their role in adults and children with asthma in the light of more recent evidence.
mesh_terms: D000085:Acetates / Q000627:therapeutic use*; D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D003521:Cyclopropanes; D003692:Delayed-Action Preparations; D006801:Humans; D007211:Indoles; D007223:Infant; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D048448:Phenylcarbamates; D011804:Quinolines / Q000627:therapeutic use*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy; D013440:Sulfides; D013449:Sulfonamides; D014105:Tosyl Compounds / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000085:Acetates; D003521:Cyclopropanes; D003692:Delayed-Action Preparations; D007211:Indoles; D020024:Leukotriene Antagonists; D048448:Phenylcarbamates; D011804:Quinolines; D013440:Sulfides; D013449:Sulfonamides; D014105:Tosyl Compounds; C093875:montelukast; C062735:zafirlukast